See more : CHL Limited (CHLLTD.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Replimune Group, Inc. (REPL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Replimune Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Team Internet Group plc (TIG.L) Income Statement Analysis – Financial Results
- LS Berkshire Hathaway (BRK-B) Tracker ETP Securities (BERK.L) Income Statement Analysis – Financial Results
- JGC Holdings Corporation (1963.T) Income Statement Analysis – Financial Results
- Barloworld Limited (BAW.JO) Income Statement Analysis – Financial Results
- ad pepper media International N.V. (APM.DE) Income Statement Analysis – Financial Results
Replimune Group, Inc. (REPL)
About Replimune Group, Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.66M | 2.45M | 4.58M | 4.14M | 1.81M | 148.00K | 109.00K | 122.00K |
| Gross Profit | -2.66M | -2.45M | -4.58M | -4.14M | -1.81M | -148.00K | -109.00K | -122.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 174.96M | 126.53M | 79.55M | 56.75M | 38.76M | 22.17M | 13.52M | 6.94M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 23.20M | 17.44M | 8.77M | 5.71M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.81M | 50.55M | 38.77M | 23.20M | 17.44M | 8.77M | 5.71M | 2.71M |
| Other Expenses | 0.00 | -5.68M | -1.06M | -665.00K | -16.00K | 451.00K | -2.06M | 626.00K |
| Operating Expenses | 234.77M | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M | 16.96M | 8.21M |
| Cost & Expenses | 234.77M | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M | 16.96M | 8.21M |
| Interest Income | 16.70M | 10.01M | 390.00K | 916.00K | 2.42M | 2.59M | 288.00K | 25.00K |
| Interest Expense | 0.00 | 4.16M | 2.22M | 3.06M | 1.92M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.66M | 2.45M | 4.58M | 4.14M | 1.81M | 148.00K | 109.00K | 122.00K |
| EBITDA | -230.20M | -170.30M | -114.41M | -76.48M | -52.60M | -28.27M | -16.85M | -8.08M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -234.77M | -177.08M | -118.31M | -79.96M | -56.20M | -30.95M | -19.23M | -9.65M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.39M | 3.08M | 278.00K | -915.00K | 3.57M | 112.00K | -473.00K | 1.94M |
| Income Before Tax | -215.39M | -174.00M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 408.00K | 288.00K | 1.16M | 2.40M | 1.90M | 451.00K | -2.06M | 125.00K |
| Net Income | -215.79M | -174.28M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -0.64 | -0.36 |
| EPS Diluted | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -0.64 | -0.25 |
| Weighted Avg Shares Out | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 30.84M | 21.51M |
| Weighted Avg Shares Out (Dil) | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 30.84M | 30.84M |
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1
Replimune: Strong Data In A Highly Differentiated Space
Replimune's RP1, an oncolytic immuno-gene therapy, shows promise with a 31.4% ORR in phase 2 trials for post PD-1 melanoma and non-melanoma skin cancers. RP2, adding an anti-CTLA-4 component to RP1, demonstrated a 29.4% ORR in phase 1 trials, with...
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with nivolumab in patients with advanced melanoma Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy,...
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will host investor...
Replimune (REPL) Gains on Positive Data From Melanoma Study
Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present...
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast...
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response consistent with the previously reported 6-month data from IGNYTE trial -- --...
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology...
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
WOBURN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended...
Source: https://incomestatements.info
Category: Stock Reports